CB has told us. They are self funding trials and they are pegged to income. dilution to fund trials was yesterday. Two things IMHO CB and the board are after or will gain is
1.) A fairer valuation in SP
2.) Opportunities via access to large pools of BIOTECH funds to add value for a strategic takeover of IP knowledge and HR if something presents itself.
The question I have is
Do they have something in mind or are they getting ready go on the hunt?
AIMHO
ER
Ann: Telix to File Registration Statement for Proposed US IPO, page-11
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.45 |
Change
0.520(2.48%) |
Mkt cap ! $7.178B | |||
| Open | High | Low | Value | Volume |
| $20.83 | $21.50 | $20.80 | $17.54M | 824.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2037 | $21.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 12320 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |